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Single-Stranded Phosphorothioated Regions
Enhance Cellular Uptake of Cholesterol-Conjugated
siRNA but Not Silencing Efficacy
Socheata Ly,1 Dimas Echeverria,1 Jacquelyn Sousa,1 and Anastasia Khvorova1
1RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01605, USA
Small interfering RNAs (siRNAs) have potential to silence
virtually any disease-causing gene but require chemical modifi-
cations for delivery to the tissue and cell of interest. Previously,
we demonstrated that asymmetric, phosphorothioate (PS)-
modified, chemically stabilized, cholesterol-conjugated
siRNAs, called hsiRNAs, support rapid cellular uptake and effi-
cient mRNA silencing both in cultured cells and in vivo. Here,
we systematically evaluated the impact of number, structure,
and sequence context of PS-modified backbones on cellular up-
take and RNAi-mediated silencing efficacy. We find that PS en-
hances cellular internalization in a sequence-dependent
manner but only when present in a single-stranded but not
double-stranded region. Furthermore, the observed increase
in cellular internalization did not correlate with functional
silencing improvement, indicating that PS-mediated uptake
may drive compounds to non-productive sinks. Thus, the pri-
mary contributing factor of PS modifications to functional ef-
ficacy is likely stabilization rather than enhanced cellular up-
take. A better understanding of the relative impact of
different chemistries on productive versus non-productive up-
take will assist in improved design of therapeutic RNAs.
INTRODUCTION
Small interfering RNA (siRNA)-based drugs have therapeutic poten-
tial to specifically target and silence any disease-causing gene.1–3
However, naked siRNAs are prone to degradation by nucleases as
well as too large and too hydrophilic to be internalized into cells on
their own. To overcome these physiological barriers, extensive chem-
ical modifications are necessary to provide protection from nucleases
and allow the oligonucleotides to enter the cell. Currently, conjugate-
mediated delivery is being realized as the clinically dominant delivery
paradigm, with a single administration supporting up to 6- to
12-month silencing efficacy in liver, brain, and other tissues evaluated
in different models ranging from rodents to humans.4,5 Sustained
therapeutic efficacy relies on conjugate-mediated delivery in conjunc-
tion with extensive chemical stabilization. A broad range of conju-
gates can be used to enhance cellular internalization, including N-ace-
tylgalactosamine (GalNAc),6 cholesterol,7,8 and docosahexaenoic acid
(DHA),9 which allow the compounds to be internalized through a
subset of the endocytic pathway, accumulating to a significant extent
in endosomes and lysosomes.10–12 Endosomal entrapment is believed
to create an intracellular depot of oligonucleotides, and subsequent
slow cytoplasmic release results in continuous loading of the endog-
enous RNAi enzymatic machinery, the RNA-induced silencing com-
plex (RISC), translating into multi-month efficacy. This model relies
on the stability of the oligonucleotides inside the highly aggressive
biological environment, such as lysosomes, and thus requires exten-
sive chemical stabilization.
A combination of sugar and backbone modification chemistries is
necessary to support sustained silencing. Phosphorothioate (PS) is
the most commonly used backbone modification, since it does not
dramatically change the overall RNA structure and thus is highly
compatible with multiple enzymatic interactions inside the cell.
Indeed, PS modifications are principally responsible for tissue distri-
bution and cellular internalization of antisense oligonucleotides
(ASOs), another class of therapeutic RNAs.13 There are multiple
studies looking at the mechanism of PS contribution on cellular inter-
nalization, but it is likely due to enhanced hydrophobicity and thus
multiple interactions with serum proteins, cellular receptors, and
trafficking proteins.14–16 In siRNAs, introduction of PS modification
enhances terminal stability and is used in all clinically advanced
modification patterns and believed to contribute to the efficiency of
cellular uptake.13,17,18
We have previously extensively characterized the behavior in cultured
cells and in vivo of a cholesterol-conjugated, asymmetric, fully chem-
ically stabilized siRNA with an alternating 20-fluoro/20-O-methyl
pattern along with PS on all four termini of the duplex, called hsiRNA.
hsiRNA contains a single-stranded, 5-nt overhang at the 30 end of the
antisense strand that is fully PS-modified (PS tail), which is believed
to enhance cellular uptake by a mechanism similar to ASO cellular
internalization.11,19 When compared in vivo, the presence of the fully
phosphorothioated tail results in significantly enhanced tissue accu-
mulation of modified siRNAs even with different conjugates.20 On
the other hand, fully PS-modified oligonucleotides can elicit strong
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toxicity,15,21 whereas reduction in PS content has been shown to be a
successful strategy for the development of compounds with a better
safety profile.22,23
To this end, we sought to systematically evaluate the impact of the
structure (single-stranded versus double-stranded) and extent of PS
modifications on the efficiency of hydrophobic siRNA cellular inter-
nalization and RISC-mediated silencing. We demonstrate that reduc-
tion of PS content results in a significant decrease of the cellular up-
take but is not directly correlated to loss of silencing efficacy.
RESULTS
Structures and Chemical Modification Patterns of Self-
Delivering siRNA Compounds Used in the Study
In order to evaluate the extent to which the structural context of
PS modifications affects the intracellular trafficking of hydrophobi-
cally modified siRNAs, we synthesized a panel of variants of a well-
studied hydrophobic siRNA configuration called hsiRNA (parent).19
hsiRNAs are asymmetric (20-nt antisense strand, 15-nt sense strand)
siRNAs where all sugars are modified with an alternating 20-fluoro
(F)/20-O-methyl (OMe) pattern, terminal backbones are protected
with PS, and the sense strand is modified with cholesterol. The parent
configuration contains seven PS modifications on the antisense 30
end, generating a 5-nt-long fully phosphorothioated tail. The panel
consisted of compounds lacking PS completely, only in the antisense
strand, as well as asymmetric configurations with different numbers
of PS modifications on the antisense 30 end (Figure 1). In addition,
we changed the length of the sense strand (15-, 18-, and 20-mer) to
evaluate the degree of importance of the single-stranded nature of
the PS tail for cellular uptake.
hsiRNAs are efficiently internalized by cells through simple addition
to themedia. Uptake is mostly driven by the early endosome antigen 1
(EEA1)-associated endocytic pathway in COS-7 or HeLa cells.11 The
oligonucleotides are labeled with Cy3, which allows evaluation of
intracellular distribution. Consistent with previously reported data,
we observed significant entrapment of internalized siRNAs in
EEA1-enriched endosomes in both COS-7 and HeLa cells (Fig-
ure 1B).11 Interestingly, there is practically no visual co-localization
with calnexin (rough endoplasmic reticulum [ER] marker, putative
RISC-nucleation point)24 at 24 h, indicating that the majority of visu-
ally detectable oligonucleotides are trapped in biologically inactive
compartments, at least at the time points tested. Furthermore, the
observed co-localization with EEA1 (early endosome) and lysosomal
associated membrane protein 1 (LAMP1; lysosomal marker) shows
very different spatial distribution patterns. hsiRNAs seem to be sur-
rounded within EEA1-enriched endosomes, whereas with LAMP1,
we observed partial co-localization where the vesicles enriched with
siRNAs and LAMP1 seem to be stacking on each other with partial
intersect.
Decreasing the Overall PS Content Decreases Cellular Uptake
and Silencing Activity of Hydrophobically Modified siRNAs
Using this panel of hsiRNAs (Figure 1), we next evaluated the impact
of oligonucleotide structure and PS content on cellular uptake and
silencing activity. The high-PS-content parent configuration showed
the highest degree of cellular uptake, consistent with previously re-
ported data (Figure 2).19 The sense strand alone, which contains
both cholesterol and Cy3 label (sense strand only), shows no detect-
able cellular internalization, confirming our notion that the presence
of the guide-strand-derived PS tail is contributing to the efficient up-
take. This process relies on both the PS tail and cholesterol, as the
oligo lacking cholesterol (no-cholesterol) also shows minimal cellular
internalization.
Furthermore, we synthesized three other configurations: 0PS which
lacks PS altogether; AS-0PS, which has no PS in the guide strand;
and AS-0PS-15-mer, which is a short 15 bp duplex lacking PS in
the guide strand. All three configurations, which all lack PS-modified
tails, showed limited cellular uptake but at higher levels than the up-
take observed for sense strand alone and no-cholesterol-containing
configurations. Representative images for the internalization kinetic
of the siRNA variants are shown in Figure 2A. To ensure consistency
of the observed phenomena, we quantified cellular fluorescence for
75–100 individual images per oligo per time point and repeated these
experiments at least twice (see Materials andMethods). The summary
of the data is shown in Figure 2B, quantitatively supporting the visual
observation that the presence of both the PS tail and cholesterol are
required for efficient cellular uptake (p < 0.0001, two-way ANOVA
for all hsiRNAs compared to the parent).
To evaluate how the observed decrease in uptake impacted silencing
efficacy, HeLa cells were treated with hsiRNA variants at seven con-
centrations to establish half maximal inhibitory concentration (IC50)
values for gene silencing. For this experiment, we used a previously
validated siRNA sequence targeting the huntingtin (HTT) gene.25
Consistent with the observed significant reduction in cellular inter-
nalization, HTT silencing was substantially reduced with the oligos
lacking PS tails, showing close to two orders of magnitude reduction
in IC50 values (parent = 20 nM, 0PS = 697 nM, AS-0PS = 1,046 nM,
AS-0PS-15-mer = 1,378 nM; see Table 1). To verify that the decreased
silencing activity was due to reduction in cellular uptake and not ef-
ficiency of RISC loading, the same panel was introduced into the cells
by lipofection, removing the requirement for self-internalization. All
Figure 1. Structures and Chemical Modification Patterns of Self-Delivering siRNA Compounds Used in the Study
(A) Panel of hsiRNAs used in this study divided into four categories based on phosphorothioate (PS) content and position. Chemical modifications include alternating 20-O-
methyl/20-fluoro, PS backbone, and cholesterol covalently linked at the 30 end of the sense strand by a tetraethylene glycol (TEG) linker. (B) Top row: COS-7 cells transiently
expressing GFP-EEA1 were treated with 0.25 mM hsiRNA and fixed after 3 h. Middle and bottom rows: HeLa cells treated with 0.25 mM hsiRNA and immunostained with
either calnexin (middle row) or LAMP1 (bottom row) and fixed after 24 h. All cells were imaged on a confocal microscope or structured illumination microscope (SIM). Scale
bars, 10 mm or 1 mm for insets.
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compounds (except sense strand only and the 15-mer duplex, which
are not expected to efficiently enter into RISC as well)21,26–28 were
able to silence mRNA just as well as the parent sequence, indicating
that the change in self-delivering silencing efficiency is mainly driven
by disruption of self-internalization (Figure S1).
Phosphorothioate-Mediated Antisense Strand Terminal
Stabilization, but Not Enhanced Cellular Uptake, Contributes to
Productive Silencing Efficacy
We clearly demonstrated that the presence of the PS tail enhances
cellular internalization of cholesterol-modified siRNAs and corre-
sponding silencing efficacy. While PS modifications are expected
to enhance cellular receptor interaction and thus uptake, they also
significantly enhance siRNA stability by providing protection from
30 to 50 nucleases.13 To deconvolute the potential dual roles of PS,
we synthesized two other hsiRNA variants where the 30 ends of
the antisense strands were protected from exonuclease degradation
by terminal incorporation of inverted dT (idT) in combination with
a single terminal PS modification (AS-1PS-idT) (Figure 3A). This
configuration is expected to provide significant 30 to 50 stabilization
to the antisense strand in the absence of extensive PS modifica-
tions.29 As a control, the parent oligo with the terminal idT modi-
fication was also synthesized with the number of PSs unchanged
(AS-7PS-idT).
AS-7PS-idT showed only slightly decreased internalization efficiency
compared to the parent compound, while reduction of PS modifica-
tions from seven to one (AS-1PS-idT) resulted in a significant reduc-
tion of cellular uptake (p < 0.0001, two-way ANOVA for all hsiRNAs
compared to the parent), similar to that of the no-PS-containing com-
pound previously tested (Figure 3B). However, despite the difference
in PS content, both 30 idT-modified variants (AS-7PS-idT and
AS-1PS-idT) showed identical silencing efficacy that was approxi-
mately an order of magnitude less than the parent oligo containing
high PS (IC50 values: parent = 20 nM, AS-7PS-idT = 223 nM, AS-
1PS-idT = 229 nM, see Table 1; Figure 3C). Given that idT-stabilized
reduced PS content oligos showed significantly lower uptake, this was
highly surprising, indicating that the fraction of internalized com-
pound available for RISC loading was actually higher for the low-
PS configuration (AS-1PS-idT).
To evaluate if the observed decrease in activity compared to the
parent is due to the negative impact of terminal idT incorporation
on RISC assembly, the compounds were introduced into the cells
Figure 2. Decreasing the Overall PS Content Decreases Cellular Uptake and Silencing Activity of Hydrophobically Modified siRNAs
(A) HeLa cells were treated with different hsiRNAs (0.25 mM), fixed at the indicated time points, and imaged on widefield fluorescence microscopy (n = 75–100 images per
hsiRNA per time point; see Materials and Methods). Scale bars, 100 mm. (B) Quantification of cellular uptake kinetic from (A) fit to a semi-log line. Shaded area indicates 95%
confidence interval. (C) Seven-point dose response performed in HeLa cells. HTT mRNA levels were quantified by QuantiGene Assay (Thermo Fisher) after 72 h treatment
with hsiRNA. Representative data shown as mean ± SD (n = 3 technical replicates) from at least two independent experiments. UNT, untreated. ****p < 0.0001 (two-way
ANOVA, compared to hsiRNA [parent]).
Table 1. Summary of hsiRNA Cellular Uptake and Silencing Efficacy
hsiRNA
No. of PS at
AS 30 End
No. of PS on AS
30 Overhang (PS Tail)
Cellular Uptake (Slope
of Semi-log Fit)
No Transfection Reagent
(Self-Delivery) IC50 (nM)
Lipid-Mediated
Transfection IC50 (pM)
hsiRNA (parent) 7 5 4.883 20 7.1
0PS 0 0 0.767 697 2.6
AS-0PS 0 0 0.431 1,046 2.1
AS-0PS-15-mer 0 0 0.431 1,378 2,874
Sense strand only N/A N/A 0.013 ND ND
No cholesterol 7 5 0.004 ND ND
AS-5PS-tail 5 5 3.070 19 2.8
AS-3PS-tail 3 3 2.451 64 3.7
AS-1PS-tail 1 1 1.515 101 1.7
AS-7PS-idT 7 + idT 5 4.050 223 70
AS-1PS-idT 1 + idT 1 0.962 229 53
20-20-mer 7 0 1.626 18 <1
20-18-mer 7 2 2.006 15 <1
sFLT 7 5 7.069 ND ND
HTT15/sFLT5 7 5 5.480 ND ND
sFLT15/HTT5 7 5 3.960 ND ND
Comparison and quantification of all hsiRNAs used in this study. HeLa cells were treated with hsiRNA and mRNA levels were measured 72 h later. N/A, not applicable; ND, not
determined.
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by lipofection (Figure 3C). Similarly, the idT-modified configurations
showed up to 10-fold lower silencing activity compared to the parent
compound (IC50 values: parent = 7.0 pM, AS-7PS-idT = 70 pM, AS-
1PS-idT = 53 pM; see Table 1). Thus, the observed decrease in
silencing efficacy is likely due to 30 idT interference with the PAZ
domain of Argonaute 2 (AGO2) interactions, which heavily involve
sugar stacking in the correct orientation,30 one of the major contrib-
uting factors for productive RISC assembly.31–33 Together, these re-
sults support the notion that the presence of a single-stranded PS
tail enhances gross, but not productive, uptake of siRNAs, and the sta-
bilizing feature of PS modification is a significant contributing factor
for efficient mRNA silencing.
Five Terminal Phosphorothioates Are Sufficient to Support Fully
Productive Silencing
Given that the PS-mediated antisense 30 end stabilization is important
for activity, we next decided to titrate the number of PS tail modifica-
tions sufficient to maintain productive silencing. We synthesized a
panel of compounds with different numbers of PS modifications in
the tail: seven PSs (parent), five PSs (AS-5PS-tail), three PSs (AS-
3PS-tail), and one PS (AS-1PS-tail). As expected, reducing the num-
ber of PS modifications had a profound negative impact on cellular
internalization (Figure 4A). The compounds containing one or three
PS modifications showed background (similar to no PS) levels of
cellular uptake. The compound with five PS modifications showed
Figure 3. Phosphorothioate-Mediated Antisense Strand Terminal Stabilization, Not Enhanced Cellular Uptake, Contributes to Productive Silencing Efficacy
(A) HeLa cells were treated with different hsiRNAs (0.25 mM), fixed at the indicated time points, and imaged on widefield fluorescence microscopy (n = 75–100 images per
hsiRNA per time point; see Materials and Methods). Scale bars, 100 mm. (B) Quantification of cellular uptake kinetic from (A) fit to a semi-log line. Shaded area indicates 95%
confidence interval. (C) Seven-point dose response performed in HeLa cells. HTT mRNA levels were quantified by QuantiGene Assay (Thermo Fisher) after 72 h treatment
with hsiRNA. Representative data shown as mean ± SD (n = 3 technical replicates) from at least two independent experiments. hsiRNA (parent sequence) data are the same
data in Figure 2 and are shown again for reference. UNT, untreated. *p < 0.05, ***p < 0.001, ****p < 0.0001 (two-way ANOVA, compared to hsiRNA [parent]).
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cellular internalization in between the parent and background levels
(Figure 4B, p < 0.0001, two-way ANOVA for all hsiRNAs compared
to the parent). These results indicate that at least five PS backbones
are necessary to promote efficient cellular internalization, consistent
with data reported for ASOs, where relatively long stretches of PS
modifications were shown to be necessary to impact tissue distribu-
tion and efficacy.34
When we measured silencing activity, the five-PS-containing com-
pound was similar to the parent (IC50 values: parent = 20 nM, AS-
5PS-tail = 19 nM; see Table 1), while AS-3PS-tail and AS-1PS-tail
siRNAs demonstrated an 5-fold reduction in efficacy (IC50 values:
64 nM, 101 nM, respectively; see Table 1). Again, when these com-
pounds were transfected by lipofection, they all demonstrated very
similar IC50 values all in the single-digit picomolar range, indicating
Figure 4. Five Terminal Phosphorothioates Are Sufficient to Support Fully Productive Silencing
(A) HeLa cells were treated with different hsiRNAs (0.25 mM), fixed at the indicated time points, and imaged on widefield fluorescence microscopy (n = 75–100 images per
hsiRNA per time point; see Materials and Methods). Scale bars, 100 mm. (B) Quantification of cellular uptake kinetic from (A) fit to a semi-log line. Shaded area indicates 95%
confidence interval. (C) Seven-point dose response performed in HeLa cells. HTT mRNA levels were quantified by QuantiGene Assay (Thermo Fisher) after 72 h treatment
with hsiRNA. Representative data shown as mean ± SD (n = 3 technical replicates) from at least two independent experiments. hsiRNA (parent sequence) data are the same
data in Figure 2 and are shown again for reference. UNT, untreated, n.s., not significant. ***p < 0.001, ****p < 0.0001 (two-way ANOVA, compared to hsiRNA [parent]).
www.moleculartherapy.org
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that the observed differences are not due to RISC loading but instead
are in their cellular uptake efficiency (Figure S2). Taken together,
these data indicate that the presence of five, but not three or fewer,
PS modifications was sufficient to provide the required stabilization
for efficient self-delivering siRNA silencing activity.
Phosphorothioate-Mediated Enhancement of Cellular Uptake Is
Only Observed in a Single-Stranded, but Not Double-Stranded,
Context
The geometry of a single-stranded and double-stranded backbone
presentation to the biological environment is significantly different.35
Because the presence of the single-stranded PS-modified tail signifi-
cantly enhances cellular internalization, we decided to evaluate the
relative impact of different hsiRNA structural configurations on PS-
mediated uptake (Figure 5A). We synthesized a panel of siRNAs
that share the same antisense strand containing seven PS terminal
modifications. The identical antisense strand was annealed to sense
strands of varying lengths (15-, 18-, and 20-nt long), generating com-
pounds with identical PS compositions in different structural contexts
(single-stranded regions of 5-nt, 2-nt, and 0-nt [blunt]).
Enhanced cellular uptake was only observed in the context of an asym-
metric compound, while the blunt (20-20-mer) and 2-nt tail (20-18-
mer) variants showed low levels of internalization similar to the no-
PS compounds (p < 0.0001, two-way ANOVA for all hsiRNAs
compared to the parent). These data indicate that only PSmodification
Figure 5. Phosphorothioate-Mediated Enhancement of Cellular Uptake Is Only Observed in a Single-Stranded, but Not Double-Stranded, Context
(A) HeLa cells were treated with different hsiRNAs (0.25 mM), fixed at the indicated time points, and imaged on widefield fluorescence microscopy (n = 75–100 images per
hsiRNA per time point; see Materials and Methods). Scale bars, 100 mm. (B) Quantification of cellular uptake kinetic from (A) fit to a semi-log line. Shaded area indicates 95%
confidence interval. (C) Seven-point dose response performed in HeLa cells. HTT mRNA levels were quantified by QuantiGene Assay (Thermo Fisher) after 72 h treatment
with hsiRNA. Representative data shown as mean ± SD (n = 3 technical replicates) from at least two independent experiments. hsiRNA (parent sequence) data are the same
data in Figure 2 and are shown again for reference. UNT, untreated; n.s., not significant. **p < 0.01 (two-way ANOVA, compared to hsiRNA [parent]).
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in the single-stranded but not double-stranded context contributes to
enhanced cellular internalization. Despite the fact that the cellular up-
take of the non-asymmetric compounds was reduced (Figure 5B), the
silencing activity was again comparable to the parent sequence at the
time point tested (Figure 5C), consistent with the notion that PS-medi-
ated enhancement of cellular internalization is not contributing to pro-
ductive uptake, at least short term. As a control, these compounds were
also transfected via lipofection and showed very similar IC50 values in
the single-digit picomolar range (Figure S3).
The Sequence of the Single-Stranded Phosphorothioate Tail
Affects Cellular Uptake
We have clearly demonstrated that both the structural and chemical
configuration of the siRNA may have a profound impact on cellular
internalization. All previous experiments were done using an siRNA
sequence targeting HTT.25 In the context of ASOs, the PS-mediated
cellular uptake and tissue distribution may be heavily affected by
the sequence, as PS-mediated interactions with cell surface and intra-
cellular proteins are sequence-context dependent.36
As the enhanced cellular uptake of hydrophobic siRNA is dependent
on the presence of a single-stranded PS tail similar to a PS-containing
ASO, we decided to evaluate if the sequence context of the tail may
also have an impact on efficiency of cellular internalization. When
two different siRNAs, one targeting sFLT (siRNAsFLT) and another
targeting HTT (siRNAHTT)37 were compared, we found that
siRNAsFLT consistently showed higher cellular internalization (Fig-
ure 6A, p < 0.0001, two-way ANOVA). To ensure that this effect
was not due to a batch effect of oligonucleotide synthesis, we re-syn-
thesized both siRNAs in parallel using the same reagents and
observed the same results (data not shown).
To test if the observed differences in efficiency of cellular uptake was
due to the sequence of the single-stranded phosphorothioated 30 tail,
we synthesized a panel of chimeric sequences where the 5-nt
tail was swapped between siRNAHTT (AUAUA) and siRNAsFLT
(GAGAG) to make siRNAHTT15/sFLT5 and siRNAsFLT15/HTT5 (Fig-
ure 6A). As expected, incorporation of the “high activity” sFLT
tail in the context of the HTT sequence (siRNAHTT15/sFLT5) com-
pound significantly enhances its uptake. Likewise, changing the
sFLT1 tail to the “low activity” HTT tail resulted in a significant
decrease in cellular internalization (p < 0.0001, two-way ANOVA
for all hsiRNAs compared to the parent). Thus, sequence of the sin-
gle-stranded PS tail may contribute to the efficiency of hydrophobic
siRNA cellular internalization.
DISCUSSION
Conjugate-mediated siRNA delivery is being realized as the clinically
dominant technology, replacing lipid nanoparticle (LNP) encapsula-
tion, which was explored initially.2,38 Although the mechanism
behind LNP-mediated uptake is relatively well characterized,16,39–42
there is little known about the mechanism behind conjugate-medi-
ated internalization. A range of different conjugates have been
explored in vivo: GalNAc delivers specifically to hepatocytes, while
hydrophobic modifications enable delivery to a wide range of tissues
beyond the liver.5,43,44
We have previously demonstrated that the presence of PS modifica-
tions enhances siRNA in vivo accumulation with both hydrophobic
and GalNAc conjugates.20 In both research13 and clinical settings,1
phosphorothioates are one of the most commonly used modifica-
tions. While it is clear that PS chemistry is fundamental for ASO
in vivo activity and cellular distribution, with significant research
dedicated toward detailed understanding of this process,36 the func-
tional contribution of PS on siRNA delivery has never been systemat-
ically characterized.
In this study, we used a fully chemically stabilized, asymmetric choles-
terol-conjugated siRNA configuration as a model. A combination of a
longer guide strand (20-nt) and shorter sense strand (15-nt) generates
a compound with a fully phosphorothioated single-stranded tail,
which impacts the efficiency of cellular uptake in cultured cells and
in vivo.45 We systematically evaluated the impact of structure, num-
ber, and sequence context of the PS tail on cellular internalization and
efficacy. We demonstrate that both structural context (single-strand
versus double-stranded), number of PS backbones, and sequence
have an impact on the efficiency of cellular uptake. Surprisingly, we
found a lack of correlation between the observed enhancement of
cellular internalization and productive silencing efficacy, likely indi-
cating that PS-mediated uptake mostly drives compounds into non-
productive “sinks,” a phenomenon that has previously been described
both for ASOs46,47 and siRNAs.24,48 We also demonstrate that com-
plete dependence of productive silencing in the presence of reduced
numbers of PS modifications is likely due to these modifications
contributing to oligonucleotide stability and not internalization.
It has long been believed that the majority of internalized oligonucle-
otides are trapped non-productively in endosomes and lysosomes,
with only a small fraction of compounds becoming biologically
active.24,40,49 Here we show the significant decrease in the amount
of internalized low-PS-content siRNA compared to high-PS-content
compounds. Surprisingly, at least at short time points in cultured cells
(72 h), there is no difference in silencing IC50 values, indicating that a
relatively higher fraction of low-PS-content siRNAs is immediately
functionally available. While PS modifications have a minimal impact
on the overall shape of the oligonucleotide, they have a profound
impact on the backbone’s chemical and functional properties, result-
ing in increased affinity to both gross and selective protein interac-
tions.13 These additional contacts are likely to contribute to the
observed enhancement in cellular uptake. It is also possible that PS-
driven diversification of intracellular interactions might compete
with siRNA availability for RISC assembly, resulting in a smaller frac-
tion of the intracellular oligonucleotides becoming functionally
active. These interactions might be related to the efficiency of endo-
somal escape or other mechanisms. This paper focuses on character-
ization in cultured cells and shows that PS-derived enhancement in
productive uptake is not biologically significant. More studies are
necessary to understand the functional impact of PS-mediated
www.moleculartherapy.org
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Figure 6. The Sequence of the Single-Stranded Phosphorothioate Tail Affects Cellular Uptake
(A) HeLa cells were treated with different hsiRNAs (0.25 mM), fixed at the indicated time points, and imaged on widefield fluorescence microscopy (n = 75–100 images per
hsiRNA per time point; see Materials and Methods). hsiRNA (parent sequence) data are the same data in Figure 2 and are shown again for reference. Scale bars, 100 mm. (B)
Quantification of cellular uptake kinetic from (A) fit to a semi-log line. Shaded area indicates 95% confidence interval. Top left panel shows hsiRNAHTT and hsiRNAsFLT and their
chimeric tail-swapped sequences, hsiRNAHTT15/sFLT5 and hsiRNAsFLT15/HTT5. Other panels compare only two hsiRNAs compared at a time for clarity, showing that
hsiRNAsFLT tail sequence enhances cellular uptake compared to the hsiRNAHTT tail sequence.
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enhancement of cellular accumulation on long-term silencing
(months), which will need to be evaluated separately in the context
of each conjugate and tissue.
Cholesterol-conjugated siRNAs without any PS modifications fully
lose silencing efficacy. We show that introduction of a 30 idT at
the 30 end of the antisense strand in the context of a single PS modi-
fication allows the compound to regain efficacy close to the idT-
modified, high-PS-content control (seven PS), indicating that the
primary contributing factor of the terminal PS modification is
enhancement of stability. With that said, introduction of the idT re-
sults in decreased silencing efficacy by more than an order of
magnitude relative to the parent compound, both in self-delivering
and lipid-mediated uptake. While idT is one of the modifications
previously used for 30 guide strand stabilization,50 it is clearly not
optimal. The negative impact on efficacy is likely due to disruption
of proper PAZ domain interactions with the antisense strand’s ter-
minal bases that normally contribute to efficient RISC assembly.
Evaluation of the published PAZ domain crystal structure51,52 in
complex with an antisense strand shows multiple interactions
with the two terminal nucleotides, which will all be naturally dis-
torted in the context of an idT. Conversely, several terminal PS
modifications resulted in similar stabilization but did not negatively
affect RISC assembly.
In the context of ASOs, PS modifications are one of the primary
chemical modifications driving both distribution as well as toxicity
through a variety of possible mechanisms.15,16 The different types
of toxicities include enhanced alanine transaminase (ALT), thrombo-
cytopenia, inflammation, hepatotoxicity, and nephrotoxicity.53,54
Recently, compounds with mixed backbones (phosphorothioate
and phosphodiester) are gaining traction by demonstrating a better
ratio between efficacy and toxicity. For example, in CNS, clinically
advanced ASO utilizes a mixed backbone configuration.55 Naturally,
minimization of PS content might be considered to enhance safety of
therapeutic siRNAs. In cultured cells, five terminal PS backbones were
sufficient to support full silencing capacity. In vivo, the exact number
and location of PS backbones will need to be optimized for each con-
jugate modality individually because of the complexity of competing
biological interactions oligonucleotides that are involved; the com-
pounds need to be stable, bind to serum proteins, associate with
cellular surfaces, escape endosomes, etc. Thus, the optimal configura-
tion in cultured cells might not be translatable for in vivo use.
With ASOs, sequence is one of the critical factors affecting a com-
pound’s efficacy and distribution, even in a context of identical chem-
ical modification patterns.1,15 This is driven by a combination of ap-
tameric effects as well as sequence and chemical modifications all
contributing to PS-driven protein interactions. However, the relative
contribution of sequence is less in the context of siRNAs due to the
rigidity of its double-stranded helix structure. With that said, in the
context of asymmetric siRNAs that contain a small single-stranded
PS-modified region, this tail might be contributing to the efficiency
of cellular internalization. While the sequence impact is less profound
compared to the number and location of PS modifications, it is still
measurable and reproducible. The first possible explanation for the
observed difference in sequences is change in stability. We tested
this hypothesis but did not detect any measurable changes (data
not shown). It is more likely that the sequence context of the PS tail
may be affecting efficiency of cellular interactions similar in mecha-
nism to those reported for ASOs.15 There are multiple articles
describing functional pathways involved in productive internalization
of ASOs inside the cells; while many protein co-factors are described
(for example, lysobisphosphatidic acid,56 Sec31A,57 and Rab558), it is
clear that productive interactions are redundant and knockout of any
of the aforementioned pathways individually does not fully block pro-
ductive silencing. Thus, complete functional characterization of mo-
lecular mechanisms behind PS-enhanced uptake is technically com-
plex and will require further investigation.
In conclusion, here we present a systematic analysis of the relative PS-
modified backbone contribution to conjugate-mediated uptake of
siRNAs and show that PS enhancement of cellular internalization
might not functionally contribute to RNAi-mediated silencing, at
least in cultured cells.
MATERIALS AND METHODS
Oligonucleotide Synthesis, Deprotection, and Purification
All oligonucleotide sequences are listed in Table S1. Oligonucleotides
were synthesized using modified (20-F, 20-OMe, 30 idT) phosphorami-
dites with standard protecting groups. Solid-phase synthesis condi-
tions using a MerMade 12 (BioAutomation) or Dr Oligo 48 (Biolytic)
were performed using modified protocols. Unconjugated oligonucle-
otides were grown on controlled pore glass functionalized with a
long-chain alkyl amine and unylinker terminus (Chemgenes).
Cholesterol-conjugated oligonucleotides were synthesized on
controlled pore glass functionalized with succinyl tetraethylene glycol
(TEG) linker and cholesterol terminus (Chemgenes). Cy3 dye
(Quasar 570 CE) phosphoramidite was purchased from (Gene-
Pharma). Phosphoramidites were prepared at 0.1 M in anhydrous
acetonitrile (ACN), with added dry 15% dimethylformamide
(DMF) in the 20-OMe U amidite. 5-(Benzylthio)-1H-tetrazole
(BTT) was used as the activator at 0.25 M. Detritylations were per-
formed using 3% trichloroacetic acid in dichloromethane. Capping
was done with non-tetrahydrofuran-containing reagents CAP A,
20% n-methylimidazole in ACN and CAP B, 20% acetic anhydride
(Ac2O), 30% 2,6-lutidine in ACN (Synthesis reagents were purchased
at AIC). Sulfurization was performed with 0.1 M solution of 3-[(di-
methylaminomethylene)amino]-3H-1,2,4-dithiazole-5-thione
(DDTT) in pyridine (ChemGenes) for 3 min. Phosphoramidite
coupling times were 3 min for all amidites used.
Deprotection and Purification of Oligonucleotides
Both sense and antisense strands were cleaved and deprotected using
40% aqueous methylamine at 45C for 60 min. The oligonucleotide
solutions were then cooled in a freezer for a few minutes and filtered
to remove the control pore glass from the cleaved oligo. The filtrate
was cooled with dry ice and then dried under vacuum in a Speedvac.
www.moleculartherapy.org
Molecular Therapy: Nucleic Acids Vol. 21 September 2020 1001
The resulting pellets were re-suspended in 5% ACN in water. The pu-
rification of antisense strands was performed on an Agilent 1100 se-
ries system, equipped with an Agilent PL-SAX, polymer ion exchange
column (10  100 mm), or Source Q anion exchange resin (GE
Healthcare) (10  100 mm custom-packed column) using the
following conditions: eluent A, 20% ACN, 20 mM NaAc (pH 5);
eluent B, 1 M sodium perchlorate in 20% ACN; gradient, 0% B
2 min, 35% B 12 min, clean and re-equilibration to initial conditions
6 min. Purification of sense strands was performed on the same
equipment but equipped with a PRP-C18, a polymer reverse phase
column (10  100 mm), using the following conditions: eluent A,
50 mM sodium acetate in 5% ACN; eluent B, ACN; gradient, 0% B
2 min, 0%–40% B 1 min, 40%–70% B 9 min, clean and re-equilibra-
tion 6 min. Temperature, 70 C, and flow rate, 10 mLmin1, were the
same in both cases. Peaks were monitored at 260 nm, and 550 nm for
labeled oligonucleotides. The pure oligonucleotide fractions were
collected, individually characterized by liquid chromatography-
mass spectrometry (LC-MS), combined, frozen, and dried in a Speed-
vac overnight. Oligonucleotides were re-suspended in 5% ACN, de-
salted through fine Sephadex G-25 (GE Healthcare) (15  200 mm
custom-packed column), and lyophilized. All reagents mentioned
above were purchased from Sigma Aldrich and used as per manufac-
turer’s instructions, unless otherwise stated.
LC-MS Analysis of Oligonucleotides
The identity of oligonucleotides was established by LC-MS analysis
on an Agilent 6530 accurate mass Q-TOF LC-MS machine using
the following conditions: buffer A: 100 mM hexafluoroisopropa-
nol/9 mM triethylamine in LC-MS grade water; buffer B:
100 mM hexafluoroisopropanol/9 mM triethylamine in LC-MS
grade methanol; column, Agilent AdvanceBio oligonucleotides
C18; gradient antisense, 0% B 1 min, 0%–30% B 8 min, clean
and re-equilibration 4 min; gradient sense, 0% B 1 min, 0%–50%
B 0.5 min, 50%–100% B 8 min, clean and re-equilibration
4 min; temperature, 45C; flow rate, 0.5 mL min1, UV
(260 nm) and (550 nm for labeled oligonucleotides). MS parame-
ters: source, electrospray ionization; ion polarity, negative mode;
range, 100–3,200 m/z; scan rate, 2 spectra s1; capillary voltage,
4,000; fragmentor, 180 V. All reagents mentioned above were pur-
chased form Sigma Aldrich and used as per manufacturer’s in-
structions, unless otherwise stated.
Cell Culture and Transfection
Both HeLa and COS-7 cells were maintained in DMEM (Invitro-
gen) supplemented with 100 U/mL penicillin streptomycin
(Invitrogen), and 10% fetal bovine serum (FBS) (Atlanta Biologicals)
at 37C and 5% CO2. For GFP-EEA1 transfections, calcium
phosphate was used to transfect 1 mg DNA.11 The cells were then
washed with fresh media after 16 h and allowed to grow for an addi-
tional 24 h.
Cellular Uptake
HeLa cells were seeded at a density of 200,000 cells/well in 12-well
glass-bottom plates (MatTek P12G-1.5-10-F) in DMEM and 3%
FBS and grown overnight. The next day, the cells were treated with
0.25 mM siRNA in fresh media. At different time points (1, 2, 4, 8,
or 24 h), the cells were washed twice with ice-cold PBS and then fixed
in 10% neutral-buffered formalin for 10 min at room temperature
(RT) (Sigma HT501128-4L). The cells were then washed three times
with PBS for 5 min each and then stained with 40,6-diamidino-2-phe-
nylindole (DAPI) (Thermo Fisher D1306) or Hoechst 33342
(Thermo Fisher H3570). Fluorescence microscopy images were ac-
quired with a Leica DMi8 widefield fluorescence microscope using
the Navigator module to take 75–100 images per well. After image
acquisition, images were exported in 16-bit tagged image file format
(TIFF) format from the Leica LAS X software and processed in Fiji
v1.52p to quantify the kinetics of siRNA cellular uptake by measuring
the mean intensity for the Cy3 channel and normalizing to the num-
ber of cells per image.59–61 The kinetic was plotted in GraphPad Prism
8 software and fit to a semi-log line.
Immunofluorescence
HeLa cells were seeded at a density of 2  105 cells in 35 mm
dishes (MatTek P35G-0.170-14-C) in DMEM + 3% FBS and
grown overnight. The next day, the cells were treated with
0.25 mM siRNA. At the indicated time points, the cells were fixed
as described above, permeabilized for 15 min at RT (0.1% Triton
X-100, 0.1% Tween-20 in PBS), washed three times with PBST
(0.1% Tween-20 in PBS) for 5 min each, blocked for 1 h at RT
(1% wt/vol BSA, 5% goat serum, 0.1% Triton X-100 in PBS),
and then washed three times with PBST for 5 min each. The cells
were incubated with primary antibody overnight at 4C, washed
three times with PBST for 5 min each, and then incubated with
secondary antibody for 1 h at RT and washed three times with
PBS for 5 min each. All antibodies were diluted in 1% wt/vol
BSA, 0.1% Triton X-100 in PBS. The cells were then stained
with DAPI (1 mg/ml) as described above and mounted with Vec-
taShield H-1000 mounting medium. Primary antibodies used
were LAMP1 (Cell Signaling 9091S, 1:200) and calnexin (Abcam
ab31290, 1:1000). Secondary antibody used was anti-rabbit Alexa-
Fluor-488 (Invitrogen A-11008, 1:500).
Super-resolution three-dimensional structured illumination micro-
scopy (3D-SIM) images were acquired on a DeltaVision OMX V4
(GE Healthcare) equipped with a 60/1.42 NA PlanApo oil immer-
sion lens (Olympus); 405, 488, 568, and 642 nm solid-state lasers;
and sCMOS cameras (pco.edge). Image stacks of 10 mm with
0.125 mm thick z sections and 15 images per optical slice (3 angles
and 5 phases) were acquired using immersion oil with a refractive
index of 1.514. Images were reconstructed using Wiener filter set-
tings of 0.008 for the 405 channel, 0.006 for the 528 channel, and
0.003 for the 508 and 683 channels. Optical transfer functions
(OTFs) were measured specifically for each channel with SoftWoRx
6.1.3 (GE Healthcare) to obtain super-resolution images with a
2-fold increase in resolution both axially and laterally. Images
from different color channels were registered using parameters
generated from a gold grid registration slide (GE Healthcare) and
SoftWoRx 6.5.2 (GE Healthcare).
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Gene Expression Analysis
To measure silencing activity, we performed a 7-point dose response,
with concentrations ranging from 0 mM to 1.5 mM, after 72 h. All h-
siRNAs use a targeting sequence for huntingtin (HTT) mRNA, which
has previously been validated.25 Briefly, HeLa cells, resuspended in
DMEM with 6% FBS and without antibiotics, were added into each
well of a 96-well plate with a density of 5,000 cells/50 mL per well.
hsiRNA was diluted to two times final concentration in serum-free
OptiMEM, and 50 mL of compound was added to each well for a final
volume of 100 mL/well and a final concentration of 3% FBS. The
mixture was incubated under standard conditions for 72 h and
then cells were lysed and processed according to the manufacturer’s
recommended protocol using the Quantigene bDNA Assay 2.0
(Thermo Fisher QS0011) and were normalized to the housekeeping
gene HPRT. Briefly, cells were lysed in 250 mL diluted lysis mixture
(1:2 lysis mixture:water) with 0.167 ug/mL proteinase K (Thermo
Fisher QS0103) for 30 min at 55C. Cell lysates were mixed thor-
oughly, and 20–80 mL of lysate were added to a bDNA capture plate
along with 0–60 additional diluted lysis mixture without proteinase K
to fill up to 80 mL total volume. Probe sets were diluted as specified in
Thermo Fisher protocol, and 20 mL of either human HTT (Thermo
Fisher SA-50339) or HPRT (Thermo Fisher SA-10030) were added
to each well of capture plate to a final volume of 100 mL. Lumines-
cence was detected on a Tecan M 1000.
Statistical Analysis
Data were analyzed using GraphPad Prism 8 software (https://www.
graphpad.com/scientific-software/prism/). IC50 curves were fitted us-
ing log(inhibitor) versus response—variable slope (four parameters).
To compare dose-response curves, two-way ANOVA Tukey’s test for
multiple comparisons compared to the hsiRNA (parent) was used. p <
0.05 was considered significant.
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